Prognostic risk factors for serious complications in an inpatient population with neutropenia at the onset of a febrile episode;Factores de mal pronostico en pacientes internados con neutropenia al inicio del episodio febril

Medicina

Volumn 66, Issue 5, 2006, Pages 385-391

  Roca, Carlos Gomez ^a   Rivero, Mirza ^a   Krupitzki, Hugo ^a   Novillo, Abel ^a   Lapadula, Maria Marta ^a   Recondo, Gonzalo ^a   Milberg, Matias ^a  

^a CEMIC   (Argentina)

Author keywords

Factors; Fever; Inpatient; Neutropenia; Prognostic; Risk

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CULTURE; BODY TEMPERATURE MEASUREMENT; BREATHING RATE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COMORBIDITY; COMPLICATION; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; GENERAL HOSPITAL; HEART RATE; HEMATOLOGIC MALIGNANCY; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPOTENSION; INFECTION; KIDNEY FAILURE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUTROPHIL COUNT; PROGNOSIS; RESPIRATORY FAILURE; RISK FACTOR; SOLID TUMOR; SYSTOLIC BLOOD PRESSURE; WARD; ACUTE KIDNEY FAILURE; CANCER CENTER; CHEMICALLY INDUCED DISORDER; DIAGNOSTIC TEST; EPIDEMIOLOGY; FEVER; HOSPITALIZATION; MIDDLE AGED; NEUTROPENIA; STATISTICS; TIME;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; COMORBIDITY; DIAGNOSTIC TESTS, ROUTINE; EPIDEMIOLOGIC METHODS; FEMALE; FEVER; HOSPITALIZATION; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; RENAL INSUFFICIENCY, ACUTE; RESPIRATORY INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 33750971997     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-51.
2. Feld R. Risk assessment and risk-based therapeutic strategies in febrile neutropenia. Curr Opin Infect Dis. 2001; 14: 415-22.
3. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148: 2561-8.
4. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-22.
5. Malik A, Abbas Z, Karim M. Randomised comparision of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992; 339: 1092-6.
6. Freifeld A, Marchigiani D, Walsh T, et al. A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Eng J Med 1999; 341: 305-11.
7. Kern WV, Cometta A, DeBock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341: 312-8.
8. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of anti-microbial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
9. Paesmans M. Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents 2000; 16: 107-11.
10. Gençer S, Salepçi T, Özer S. Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients. J Infect 2003; 47: 65-72.
11. Viscoli C, Bruzzi P, Castagnola E, et al. Factors associated with bacteraemia in febrile, granulocytopenic patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 1994; 30A: 430-7.
12. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia. A multicenter randomized trial. J Natl Cancer Inst. 2001; 93: 31-8.
13. Santolaya ME, Alvarez AM, Becker A, Cofré J, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001; 19: 3415-21.
14. Jones GR, Konsler GK, Dunaway RP, Pusek SN. Infection risk in febrile, neutropenic children and adolescents. Pediatr Hematol Oncol. 1996; 13: 217-29.
15. Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breiffeld PB. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol. 1996; 14: 919-24.
16. Regazzoni CJ, Khoury M, Irrazabal C, et al. Neutropenia and the development of the systemic inflammatory response syndrome. Int Care Med 2003; 29: 135-8.
17. Blot F, Cordonnier C, Buzin A, Nitenberg G, Schlemmer B, Bastuji-Garin S. Severity of illness scores: Are they useful in febrile neutropenic adults patients in hematology wards? A prospective multicienter study. Crit Care Med 2001; 29: 2125-31.
18. Gurguet et al. Severity of illness scores for neutropenic cancer patients in an intensive care unit. Which is the best predictor? Do multiple assessment improve the predictive value? Crit Care Med 1998; 26: 488-93.
19. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G. The identification of febrile, neutropenic children with neoplastic disease a low risk for bacteremia and complications of sepsis. Cancer 1996; 77: 791-8.